According to a new report from Intel Market Research, the global Targeted PSMA Radionuclide Drug Conjugates market was valued at USD 1,821 million in 2025 and is projected to reach USD 3,218 million by 2034, reflecting a robust CAGR of 8.3 % during the forecast horizon (2025–2034). This expansion is driven by a confluence of clinical, regulatory and commercial forces that are reshaping the therapeutic landscape for advanced prostate cancer.
What are Targeted PSMA Radionuclide Drug Conjugates?
Targeted PSMA (Prostate‑Specific Membrane Antigen) radionuclide drug conjugates are precision radiotherapeutics designed to deliver a therapeutic radioisotope directly to PSMA‑expressing tumor cells. Each construct typically comprises a high‑affinity PSMA‑binding ligand or small‑molecule vector, a chelator that securely holds the radionuclide, and a therapeutic isotope such as 177Lu (beta‑emitter) or 225Ac (alpha‑emitter). The beta‑emitting agents dominate current clinical approvals, while alpha‑emitters are advancing through late‑stage trials for metastatic castration‑resistant prostate cancer (mCRPC).
Market expansion is being fueled by rising incidence of advanced prostate cancer, increasing reimbursement for radioligand therapy, and ongoing investments in isotope production capacity. At the same time, supply‑chain constraints around stable isotope availability and the need for specialized nuclear‑medicine facilities temper growth, prompting leading firms to broaden manufacturing networks and secure cold‑chain logistics.
📥 Download FREE Sample Report:
Targeted PSMA Radionuclide Drug Conjugates Market - View in Detailed Research Report
Comments
Log in or sign up to join the conversation.